[Home]   [Full version]  

Few studies consider the appropriate measurements for assessing clinical trials in children

Apr 29 ,Medicine & Health


Very few studies have asked what the appropriate measurements are for assessing treatments in clinical trials in children, according to a systematic review of paediatric clinical research conducted since 1950. The review by Ian Sinha and colleagues from the University of Liverpool, published in this week’s PLoS Medicine, also shows that few studies have involved parents and none have involved children in the process to select which measurements to use to assess clinical trials.

Before conducting a clinical trial of a new drug, researchers choose several “outcomes.” These are measurements chosen in advance of the trial to ensure that as much information as possible is provided about the drug’s safety, effectiveness and its impact on the patients’ health and daily life. Children’s bodies handle certain drugs very differently to adults – it can’t just be assumed that drugs effective in adults simply need to be scaled down to work for children – and so paediatric clinical trials need to be designed with these differences in mind.

By using a search strategy and consulting experts in paediatric clinical research, the researchers identified all the studies since 1950 that have examined the selection of outcomes in clinical trials conducted in children. Their initial search was very wide to minimize bias, leading to the retrieval of 9,000 abstracts. Only twenty-five articles met the criteria established by the review and examined the selection of outcomes in clinical research in children. These studies came from thirteen groups researching different conditions – including asthma, Crohn’s disease and cystic fibrosis – but for many paediatric areas there has been no work done into the selection of appropriate outcomes for clinical trials in children.

Reaching agreement on standard outcomes for clinical trials in children is important because it enables researchers and clinicians to compare and combine the results of clinical trials. Standardization also helps avoid selectivity and bias in the conduct of research. Several of the studies reviewed by Ian Sinha and colleagues used methods that had previously been used to select outcomes in clinical trials in adults. These include a technique in which individual opinions are sought and fed back into a group discussion before a final consensus agreement is reached, as well as a technique that involves face-to-face discussion followed by a vote. But although the groups selecting the appropriate outcomes in these studies included clinical experts and specialists in a particular paediatric condition, only three groups asked parents about the outcomes that should be included to assess the clinical trials and none of them asked children directly. < /span>

In an accompanying perspective, Mike Clarke of the UK Cochrane Centre and Trinity College, Dublin - not involved in the systematic review - suggests the approaches identified should “make it easier to plan, appraise and use initiatives that have already attempted to standardize outcomes.” But as Ian Sinha and colleagues conclude, further research is urgently required to make this process easier and more uniform and to involve children and their parents in assessing which outcomes should be used in clinical trials.

Citation: Sinha I, Jones L, Smyth RL, Williamson PR (2008) A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Med 5(4): e96.

Source: Public Library of Science

Related stories:

Post-marketing studies finding adverse events in drugs used in children
The Food and Drug Administration Modernization Act (FDAMA, 1997), designed to stimulate more drug safety studies in children, has resulted in more than 130 label changes since its inception nearly six years ago, according to researchers at Duke Children's Hospital. Their analysis appears in the September issue of Pediatrics.
Gene that causes childhood cancer neuroblastoma is found
Scientists have discovered gene mutations that are the main cause of the inherited version of the childhood cancer neuroblastoma. In addition, the researchers found that the same mutations play a significant role in high-risk forms of non-inherited neuroblastoma, the more common form of the disease.
Scientists nail childhood nerve cancer gene
Researchers have identified the hereditary gene mutations behind a deadly form of childhood cancer, opening the way to genetic tests in high-risk families, according to study released Sunday.
Teen cancer survival rates on the rise
(PhysOrg.com) -- The first national report detailing survival for teenagers and young adults with cancer shows that survival rates climbed by about 11% over two decades.
The University of Manchester findings, published in the British Journal of Cancer today, looked at survival across all cancers in people aged 13 to 24 between 1979 and 2001.
FDA approves first drug for Huntington's disease
The U.S. Food and Drug Administration today approved tetrabenazine, the first drug approved for use in the United States to treat Huntington's disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease.
Greater response to placebo in children than in adults
In a systematic review of antiepileptic drugs, Philippe Ryvlin (of the Hospices Civils de Lyon, France) and colleagues show that children with drug-resistant partial epilepsy enrolled in trials seem to have a greater response to placebo than adults enrolled in such trials. This finding is an important factor to consider when designing drug trials to be carried out in children with epilepsy.
Immune system protein accurate predictor of survival in pediatric septic shock
About 4,000 children in the United States die every year from uncontrolled infections of the body known as septic shock, and researchers are pushing the boundaries of molecular science to find new therapies that can stem the condition. But a simple measure of an immune system protein within 24 hours of being admitted to the hospital for septic shock can predict survival in children, yielding a powerful tool for diagnostics and clinical trials of new septic shock therapies, according to a research team led by Cincinnati Children's Hospital Medical Center in the Aug. 1 American Journal of Respiratory and Critical Care Medicine.
New study shows calcium significantly improves children's bone health
A recent study published in the journal Bone found that higher intakes of calcium, such as those recommended by the USDA, may significantly improve bone health in children.

News discussion:

Medicine & Health news

[Home]   [Full version]